Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
Arvinas (NASDAQ: ARVN) presented promising preclinical combination data for ARV-393, their PROTAC BCL6 degrader, at the 2025 AACR Annual Meeting. The study demonstrated significant antitumor activity in non-Hodgkin lymphoma models.
Key findings showed that ARV-393 combined with standard-of-care R-CHOP chemotherapy achieved complete tumor regressions in all treated mice. The drug also showed strong synergy when combined with biologics targeting CD20, CD19, or CD79b, and with small molecule inhibitors targeting BTK, BCL2, or EZH2.
Notably, ARV-393 increased CD20 expression, supporting its potential use with CD20-targeted therapies. A Phase 1 study (NCT06393738) is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL.
Arvinas (NASDAQ: ARVN) ha presentato dati preclinici promettenti sulla combinazione per ARV-393, il loro degrader PROTAC di BCL6, durante il Meeting Annuale AACR 2025. Lo studio ha dimostrato un'attività antitumorale significativa nei modelli di linfoma non-Hodgkin.
I risultati principali hanno evidenziato che ARV-393 combinato con la chemioterapia standard R-CHOP ha ottenuto regressioni tumorali complete in tutti i topi trattati. Il farmaco ha inoltre mostrato una forte sinergia se combinato con biologici diretti contro CD20, CD19 o CD79b, e con inibitori a piccola molecola mirati a BTK, BCL2 o EZH2.
In particolare, ARV-393 ha aumentato l'espressione di CD20, supportando il suo potenziale utilizzo con terapie mirate a CD20. Uno studio di Fase 1 (NCT06393738) sta attualmente arruolando pazienti con linfoma non-Hodgkin recidivante/refrattario, incluso DLBCL.
Arvinas (NASDAQ: ARVN) presentó datos preclínicos prometedores sobre la combinación de ARV-393, su degradador PROTAC de BCL6, en la Reunión Anual AACR 2025. El estudio demostró una actividad antitumoral significativa en modelos de linfoma no Hodgkin.
Los hallazgos clave mostraron que ARV-393 combinado con la quimioterapia estándar R-CHOP logró regresiones tumorales completas en todos los ratones tratados. El fármaco también mostró una fuerte sinergia cuando se combinó con biológicos dirigidos contra CD20, CD19 o CD79b, y con inhibidores de molécula pequeña dirigidos a BTK, BCL2 o EZH2.
Notablemente, ARV-393 aumentó la expresión de CD20, respaldando su posible uso con terapias dirigidas a CD20. Un estudio de Fase 1 (NCT06393738) está actualmente reclutando pacientes con linfoma no Hodgkin en recaída/refractario, incluyendo DLBCL.
Arvinas (NASDAQ: ARVN)는 2025년 AACR 연례 회의에서 PROTAC BCL6 분해제인 ARV-393의 유망한 전임상 병용 데이터를 발표했습니다. 연구는 비호지킨 림프종 모델에서 유의미한 항종양 활성을 보여주었습니다.
주요 결과는 ARV-393가 표준 치료법인 R-CHOP 화학요법과 병용 시 모든 처리된 쥐에서 완전한 종양 퇴축을 달성했다는 것을 보여주었습니다. 이 약물은 또한 CD20, CD19, CD79b를 표적으로 하는 생물학 제제 및 BTK, BCL2, EZH2를 표적으로 하는 소분자 억제제와 병용 시 강력한 시너지를 나타냈습니다.
특히 ARV-393는 CD20 발현을 증가시켜 CD20 표적 치료제와의 병용 가능성을 뒷받침합니다. 1상 연구(NCT06393738)가 현재 재발/불응성 비호지킨 림프종 환자, 포함하여 DLBCL 환자를 대상으로 등록 중입니다.
Arvinas (NASDAQ : ARVN) a présenté des données précliniques prometteuses sur la combinaison pour ARV-393, leur dégradeur PROTAC de BCL6, lors de la réunion annuelle AACR 2025. L'étude a démontré une activité antitumorale significative dans des modèles de lymphome non hodgkinien.
Les résultats clés ont montré que ARV-393 combiné à la chimiothérapie standard R-CHOP a permis des régressions tumorales complètes chez tous les souris traitées. Le médicament a également montré une forte synergie lorsqu'il était associé à des biologiques ciblant CD20, CD19 ou CD79b, ainsi qu'à des inhibiteurs de petites molécules ciblant BTK, BCL2 ou EZH2.
Notamment, ARV-393 a augmenté l'expression de CD20, soutenant son utilisation potentielle avec des thérapies ciblant CD20. Une étude de phase 1 (NCT06393738) recrute actuellement des patients atteints de lymphome non hodgkinien en rechute/réfractaire, y compris le DLBCL.
Arvinas (NASDAQ: ARVN) präsentierte vielversprechende präklinische Kombinationsdaten für ARV-393, ihren PROTAC-BCL6-Degrader, auf dem AACR-Jahrestreffen 2025. Die Studie zeigte eine signifikante antitumorale Aktivität in Modellen des Non-Hodgkin-Lymphoms.
Wesentliche Ergebnisse zeigten, dass ARV-393 in Kombination mit der Standard-Chemotherapie R-CHOP vollständige Tumorrückbildungen bei allen behandelten Mäusen erreichte. Das Medikament zeigte zudem eine starke Synergie in Kombination mit Biologika, die auf CD20, CD19 oder CD79b abzielen, sowie mit kleinen Molekülinhibitoren, die BTK, BCL2 oder EZH2 hemmen.
Bemerkenswert ist, dass ARV-393 die CD20-Expression erhöhte, was seine potenzielle Anwendung mit CD20-gerichteten Therapien unterstützt. Eine Phase-1-Studie (NCT06393738) rekrutiert derzeit Patienten mit rezidivierendem/refraktärem Non-Hodgkin-Lymphom, einschließlich DLBCL.
- Complete tumor regression achieved in all mice when combined with R-CHOP therapy
- Demonstrated synergistic effects with multiple standard-of-care treatments
- Increased CD20 expression, enhancing potential efficacy of CD20-targeted therapies
- Successfully advanced to Phase 1 clinical trials
- Results to preclinical studies only
- Clinical efficacy in humans yet to be demonstrated
Insights
Preclinical data shows ARV-393 achieves complete tumor regression in aggressive lymphoma when combined with standard treatments, supporting its ongoing clinical development.
Arvinas's PROTAC BCL6 degrader ARV-393 shows impressive preclinical results in aggressive lymphoma models. Unlike conventional inhibitors that simply block protein function, PROTAC technology harnesses the cell's own machinery to selectively destroy target proteins - in this case, BCL6, a transcription factor critical for lymphoma survival.
Three key combinations demonstrated significant efficacy:
- With R-CHOP chemotherapy: Complete tumor regressions in all treated mice, superior to either treatment alone
- With CD20/CD19/CD79b-targeting biologics: Enhanced tumor growth inhibition with regressions
- With targeted small molecule inhibitors (BTK, BCL2, EZH2): Superior tumor growth inhibition with regressions in all mice
Particularly noteworthy is ARV-393's ability to increase CD20 expression, potentially overcoming a major resistance mechanism to rituximab, a backbone therapy in lymphoma treatment. This suggests ARV-393 could resensitize tumors to standard therapies.
These findings provide a strong rationale for the ongoing Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma (NCT06393738). While preclinical success doesn't guarantee clinical efficacy, the consistency across multiple combination approaches and complete regressions observed suggest promising biological activity worthy of further clinical investigation.
ARV-393's synergistic activity with standard lymphoma treatments potentially expands its market opportunity and validates Arvinas's PROTAC platform technology.
The preclinical data for ARV-393 represents strategic validation for Arvinas's PROTAC technology platform in oncology. The broad combinability demonstrated with established therapies is particularly significant for three reasons:
First, the synergy with R-CHOP (standard first-line lymphoma therapy) suggests ARV-393 could enhance existing treatment paradigms rather than replace them - potentially offering a more efficient path to market adoption.
Second, ARV-393's ability to increase CD20 expression addresses a critical resistance mechanism in lymphoma treatment. If this translates clinically, it could position ARV-393 as a valuable component in treating refractory cases where current therapies fail.
Third, the multiple effective combination approaches provide development optionality for Arvinas, allowing pursuit of different clinical strategies based on emerging data.
This preclinical milestone supports Arvinas's continued investment in ARV-393's clinical development program. The ongoing Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma represents the crucial next step in determining whether these promising preclinical results will translate to patients.
For Arvinas, whose market value primarily reflects its platform potential rather than current revenues, continued positive data from its PROTAC pipeline remains essential for long-term value creation.
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors –
– Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma –
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company’s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models. The results from these preclinical studies were shared in a poster presentation at the 2025 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois.
Key findings from the studies included:
- ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), induced significantly greater tumor growth inhibition compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination.
- ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin) resulted in tumor regressions and demonstrated significantly stronger tumor growth inhibition compared with each agent alone.
- In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression.
- ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.
“Given that combination regimens are the foundation of lymphoma treatment, we are encouraged by the strength of these preclinical combination data, which demonstrate complete tumor regressions in aggressive lymphoma models,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. “We believe these preclinical data demonstrate potential for broad combinability of ARV-393 and provide a compelling rationale for considering combination strategies as we work to bring forward new therapeutic options for lymphoma patients.”
A Phase 1 study of ARV-393 is enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL (NCT06393738).
Additional detail on the ARV-393 data presentation at AACR 2025:
Poster Title: ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models
Abstract: 1655
Session Title: Degraders and Glues 2
Session Type: Experimental and Molecular Therapeutic
Location: Poster Section 18
Poster Board Number: 15
Date: Monday, April 28, 2025
Lecture Time: 9:00 a.m. – 12:00 p.m. CT
About ARV-393
ARV-393 is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. During B-cell development, tightly controlled BCL6 protein expression regulates >600 genes to facilitate rapid B-cell proliferation and tolerance of somatic hypermutation and gene recombination for antibody generation. Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6. ARV-393 is currently in a Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential for Arvinas’ investigational oral PROteolysis TArgeting Chimera (PROTAC) degrader ARV-393 to treat relapsed/refractory non-Hodgkin lymphoma; the preclinical data for ARV-393 demonstrating the potential for broad combinability and supporting continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma associated with B-cell lymphoma 6 protein (“BCL6”) dysfunction; and PROTAC-mediated degradation having the potential to address the historically undruggable nature of BCL6.. All statements, other than statements of historical facts, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-393, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials on its expected timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts:
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
What are the key findings of ARV-393's combination therapy trials presented at AACR 2025?
How does Arvinas' ARV-393 PROTAC degrader affect CD20 expression in lymphoma treatment?
What is the current development status of ARV-393 (ARVN)?
Which combination therapies showed complete regression with ARV-393 in preclinical studies?
